State Street Health Care Select Sector SPDR ETF (XLV) Covered Calls
Health Care Select Sector SPDR Fund offers targeted exposure to companies in the healthcare sector of the S&P 500. The fund invests in firms across various industries, including pharmaceuticals, health care equipment and supplies, healthcare providers and services, and biotechnology. It provides an efficient way for investors to access a diversified portfolio of established, large-cap healthcare leaders, serving as a core holding for defensive equity positioning and sector growth.
You can sell covered calls on State Street Health Care Select Sector SPDR ETF to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for XLV (prices last updated Fri 4:16 PM ET):
| State Street Health Care Select Sector SPDR ETF (XLV) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 143.26 | -2.48 | 142.77 | 143.00 | 12.8M | - | 22 |
| Covered Calls For State Street Health Care Select Sector SPDR ETF (XLV) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Apr 17 | 143 | 1.51 | 141.49 | 1.1% | 18.3% | |
| May 15 | 143 | 3.45 | 139.55 | 2.5% | 18.2% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
The Health Care Select Sector SPDR Fund is one of the oldest and most liquid exchange-traded funds in the healthcare space. It is designed to track the Health Care Select Sector Index, which includes all healthcare companies within the S&P 500. This focus on large-cap, established enterprises ensures that the portfolio is comprised of industry leaders with significant resources and global reach. The fund is market-capitalization weighted, meaning the largest companies have the greatest impact on performance.
Core Business and Products
The primary product of this fund is a highly liquid equity portfolio that represents the broad diversity of the healthcare landscape. The fund’s largest exposure is typically in pharmaceuticals, followed by health care equipment, biotechnology, and managed care providers. Major individual holdings that drive the fund include global giants like Eli Lilly, Johnson & Johnson, and AbbVie.
The fund also provides significant exposure to healthcare services and life sciences tools. Notable holdings in these sub-sectors include UnitedHealth Group, Merck & Co., and Thermo Fisher Scientific. By holding these firms in a single vehicle, the fund allows investors to capture the collective innovation of the sector, from life-saving drug development to advanced surgical robotics and administrative insurance services. The fund uses a full replication strategy to ensure high tracking accuracy.
Competitive Landscape
The fund operates in a highly competitive market for sector-specific investment products. Its primary competitors are other broad-based healthcare ETFs such as the Vanguard Health Care ETF and the iShares U.S. Healthcare ETF. While these rivals offer similar exposure, the fund is distinguished by its exclusive focus on S&P 500 constituents and its massive trading volume, which makes it a preferred tool for institutional traders.
Other significant competitors include more specialized or equal-weighted products like the Fidelity MSCI Health Care Index ETF or the Invesco S&P 500 Equal Weight Health Care ETF. Additionally, investors often compare the fund to biotechnology-specific vehicles such as the SPDR S&P Biotech ETF. The fund’s main competitive advantage lies in its cost efficiency and the deep liquidity of its associated options market, allowing for advanced hedging and income-generation strategies.
Strategic Outlook and Innovation
The strategic focus of the fund is to provide a reliable, evergreen gateway to the evolving healthcare industry. Innovation in the sector is a constant driver of the fund’s long-term value, as member companies develop new therapies for chronic diseases, utilize artificial intelligence for drug discovery, and advance personalized medicine. The fund’s passive structure ensures that the portfolio automatically adjusts to include the newest medical leaders as they enter the benchmark index.
Looking ahead, the fund is positioned to benefit from structural tailwinds such as an aging global population and increasing healthcare spending in developed markets. The integration of technology into healthcare delivery and the expansion of the "obesity drug" market are key themes that are expected to influence the earnings of top holdings. By maintaining a transparent and rules-based investment process, the fund remains a foundational choice for investors seeking to participate in the scientific and economic progress of the modern medical era.
| Top 10 Open Interest For Apr 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | SLV covered calls | 6. | QQQ covered calls | 1. | REPL covered calls | |
| 2. | EEM covered calls | 7. | GLD covered calls | 2. | BW covered calls | |
| 3. | NVDA covered calls | 8. | HYG covered calls | 3. | PTON covered calls | |
| 4. | KWEB covered calls | 9. | EWZ covered calls | 4. | USO covered calls | |
| 5. | SPY covered calls | 10. | TLT covered calls | 5. | WULF covered calls | |
Want more examples? XLU Covered Calls | XLY Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
